Journal
JOURNAL OF CLINICAL ONCOLOGY
Volume 33, Issue 29, Pages 3251-+Publisher
AMER SOC CLINICAL ONCOLOGY
DOI: 10.1200/JCO.2015.60.7804
Keywords
-
Categories
Funding
- Oncolytics Biotech (Inst)
- Genelux (Inst)
- Viralytics (Inst)
- AstraZeneca (Inst)
- Cancer Research UK [13407, S_1458, 17796] Funding Source: researchfish
- Rosetrees Trust [M444] Funding Source: researchfish
Ask authors/readers for more resources
Human papillomavirus-negative head and neck squamous cell carcinoma (HNSCC) carries a poor prognosis, and despite optimal treatment with chemoradiotherapy to the limit of tolerance, many patients will relapse. A number of methods for intensifying treatment of HNSCC have been investigated, leading to the current standards of care. Novel agents targeting tumor cell and stromal signaling, DNA damage response, and immune system are now reaching clinical trials in combination with chemoradiotherapy. In this review, we discuss the evidence for the current treatment of locally advanced human papillomavirus-negative HNSCC, as well as investigational therapies, such as hypoxia modification, molecular targeting of epidermal growth factor receptor family, vascular endothelial growth factor receptor or DNA damage response proteins in combination with radiation therapy. (C) 2015 by American Society of Clinical Oncology
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available